The “Traditional Chinese medicine regulating liver regeneration” treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data

doi:10.1007/s11684-020-0790-9

Frontiers of Medicine

2021, Vol. 15

Issue (3): 495-505 https://doi.org/10.1007/s11684-020-0790-9

本期目录

The “Traditional Chinese medicine regulating liver regeneration” treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data

Ling Dai, Xiang Gao, Zhihua Ye, Hanmin Li(

), Xin Yao, Dingbo Lu, Na Wu

Institute of Liver Diseases, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan 430061, China; Institute of Basic Theory of Chinese Medicine, Hubei Province Academy of Traditional Chinese Medicine, Wuhan 430074, China; Theory and Application Research of Liver and Kidney in Traditional Chinese Medicine, Hubei Provincial Key Laboratory, Wuhan 430074, China; Key Laboratory of Treating Chronic Liver Diseases from Liver and Kidney, State Administration of Traditional Chinese Medicine, Wuhan 430061, China

全文: PDF(467 KB) HTML

Abstract：

On the basis of real-world clinical data, the study aimed to explore the effect and mechanisms of the treatment plan of “traditional Chinese medicine (TCM) regulating liver regeneration.” A total of 457 patients with HBV-related liver failure were retrospectively collected. The patients were divided into three groups: the modern medicine control group (MMC group), patients treated with routine medical treatment; the control group combining traditional Chinese and Western medicine (CTW), patients treated with routine medical treatment plus the common TCM formula; and the treatment group of “TCM regulating liver regeneration” (RLR), patients treated with both routine medical treatment and the special TCM formula of RLR. After 8 weeks of treatment, the mortality of patients in the RLR group (12.31%) was significantly lower than those in the MMC (50%) and CTW (29.11%) groups. Total bilirubin level significantly decreased and albumin increased in the RLR group when compared with the MMC and CTW groups (P<0.05). In addition, there were significant differences in the expression of several cytokines related to liver regeneration in the RLR group compared with the MMC group. RLR treatment can decrease jaundice, improve liver function, and significantly reduce the mortality in patients with HBV-related liver failure. The mechanism may be related to the role of RLR treatment in influencing cytokines related to liver regeneration.

Key words： hepatitis B virus-related liver failure traditional Chinese medicine liver regeneration liver regeneration microenvironment cytokines

收稿日期: 2019-06-21 出版日期: 2021-06-18

Corresponding Author(s): Hanmin Li

引用本文:

. [J]. Frontiers of Medicine, 2021, 15(3): 495-505.
Ling Dai, Xiang Gao, Zhihua Ye, Hanmin Li, Xin Yao, Dingbo Lu, Na Wu. The “Traditional Chinese medicine regulating liver regeneration” treatment plan for reducing mortality of patients with hepatitis B-related liver failure based on real-world clinical data. Front. Med., 2021, 15(3): 495-505.

链接本文:

https://academic.hep.com.cn/fmd/CN/10.1007/s11684-020-0790-9
https://academic.hep.com.cn/fmd/CN/Y2021/V15/I3/495

Fig.1

Characteristic	MMC (n = 96)	CTW (n = 158)	RLR (n = 203)	P value
Age (year, $x ¯ ± s$ )	47.65±12.96	47.68±12.91	47.32±12.98	0.959
Male (n (%))	79 (82.29)	128 (81.01)	168 (82.76)	0.91
Disease course (year, $x ¯ ± s$ )	11.84±11.98	11.16±10.52	12.24±9.76	0.63
Acute-on-chronic (subacute) liver failure (n (%))	55 (57.29)	84 (53.16)	103 (50.74)	0.569
Chronic liver failure (n (%))	41 (42.71)	74 (46.84)	100 (49.26)	0.569

Tab.1

Tab.2

Fig.2

Tab.3

Tab.4

Fig.3

1	Z Ma, Y Wu. Current status of liver failure treatment. J Clinic Hepatol (Lin Chuang Gan Dan Bing Za Zhi) 2016; 32: 1668–1672 (in Chinese)
2	ZG Zhao, T Han, YT Gao, YY Gao, Y Zhang, ZP Wu. Causes and clinical outcomes of acute-on-chronic liver failure in patients with hepatitis B virus infection: an analysis of 289 cases. World Chin J Dig (Shi Jie Hua Ren Xiao Hua Za Zhi) 2009; 17(31): 3269–3272 (in Chinese) https://doi.org/10.11569/wcjd.v17.i31.3269
3	Organization Committee of 13th Asia-Pacific Congress of Clinical Microbiology and Infection. 13th Asia-Pacific Congress of Clinical Microbiology and Infection Consensus Guidelines for diagnosis and treatment of liver failure. Hepatobiliary Pancreat Dis Int 2013; 12(4): 346–354 https://doi.org/10.1016/S1499-3872(13)60055-7
4	Q Ning, L Zhu, WM Yan. Prewarning of severe acute aggravation of chronic hepatitis B. Chin J Hepatol (Zhonghua Gan Zang Bing Za Zhi) 2010; 18(11): 805–807 (in Chinese) pmid: 21138624
5	XM Tan, Q Ning. The progress in molecular mechanism of severe hepatitis. Int J Epidemiol Infect Dis (Guo Ji Liu Xing Bing Xue Chuan Ran Bing Xue Za Zhi) 2004; 31: 150–157 (in Chinese)
6	HM Li. Basic and clinical research of traditional Chinese medicine regulating and controlling liver regeneration. Chin Arch Tradit Chin Med (Zhonghua Zhong Yi Yao Xue Kan) 2017; 35: 1927–1931 (in Chinese)
7	Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association. Diagnostic and treatment guidelines for liver failure (2012 version). Chin J Hepatol (Zhonghua Gan Zang Bing Za Zhi) 2013; 21(3): 177–183 (in Chinese) pmid: 23967737
8	SN Zhou, N Zhang, LF Wang, J Li. Clinical research of hepatitis B-related liver failure by TCM and WM combination therapy. Chin Hepatol (Gan Zang) 2012; 17: 36–38 (in Chinese)
9	HM Li. Progress and prospect of regulation of liver regeneration by traditional Chinese medicine. World Chin J Dig (Shi Jie Hua Ren Xiao Hua Za Zhi) 2017; 25(15): 1338 (in Chinese) https://doi.org/10.11569/wcjd.v25.i15.1338
10	LF Wang, J Li, FY Li. Analysis the curative efficacy of combination of Chinese and Western medicine treatment the hepatitis B virus associated hepatic failure. Chin J Integr Tradit West Med Liver Dis (Zhong Xi Yi Jie He Gan Bing Za Zhi) 2018; 28: 70–74 (in Chinese)
11	M Gong, C Zhou, N Zhang. Clinical effect of integrated traditional Chinese and Western medicine therapy in patients with hepatitis B virus-related acute-on-chronic liver failure complicated by hepatic encephalopathy. J Clinic Hepatol (Lin Chuang Gan Dan Bing Za Zhi) 2018; 34: 795–800 (in Chinese)
12	HM Li, ZH Ye, J Zhang, X Gao, YM Chen, X Yao, JX Gu, L Zhan, Y Ji, JL Xu, YH Zeng, F Yang, L Xiao, GG Sheng, W Xin, Q Long, QJ Zhu, ZH Shi, LG Ruan, JY Yang, CC Li, HB Wu, SD Chen, XL Luo. Clinical trial with traditional Chinese medicine intervention “tonifying the kidney to promote liver regeneration and repair by affecting stem cells and their microenvironment” for chronic hepatitis B-associated liver failure. World J Gastroenterol 2014; 20(48): 18458–18465 https://doi.org/10.3748/wjg.v20.i48.18458 pmid: 25561817
13	HM Li. Discussion on the treatment principle of “tonifying the kidney to regulate stem cells transforming the liver”. Chin Arch Tradit Chin Med (Zhonghua Zhong Yi Yao Xue Kan) 2012; 30: 937–940 (in Chinese)
14	HM Li. Regulation of liver regeneration: research progress and prospect. World Chin J Dig (Shi Jie Hua Ren Xiao Hua Za Zhi) 2015; 23(21): 3337–3343 (in Chinese) https://doi.org/10.11569/wcjd.v23.i21.3337
15	HM Li. The unbalance of EMT/MET and “marrow cells cannot differentiate into liver cells”. Chin J Integr Tradit West Med Liver Dis (Zhong Xi Yi Jie He Gan Bing Za Zhi) 2012; 21: 385–389 (in Chinese)
16	HM Li. Evolution rule of jaundice syndromes in chronic sever hepatitis. Chin J Integr Tradit West Med Liver Dis (Zhong Xi Yi Jie He Gan Bing Za Zhi) 2009; 19: 148–150 (in Chinese)
17	HM Li. Comprehensive and systematic in-depth study on traditional Chinese medicine for regulating liver regeneration. Chin J Integr Tradit West Med Liver Dis (Zhong Xi Yi Jie He Gan Bing Za Zhi) 2007; 17: 129–132 (in Chinese)
18	HM Li, X Gao, XS Yan, AP Ming, YQ Peng. Study on molecular mechanism of Zuoguiwan in promoting bone marrow cells to form hepatic cells. J Tradit Chin Med (Zhong Yi Za Zhi) 2006; 47: 778–780 (in Chinese)
19	HL Song, HM Li, LS Lin, X Gao, BB Zhao, J Zhang, Y Wu, XS Yan, L Xiao. Effects of Diwuyanggan capsule on liver regeneration of rat with deficiency of kidney essence and liver blood. Chin J Integr Tradit West Med Liver Dis (Zhong Xi Yi Jie He Gan Bing Za Zhi) 2013; 23: 90–92 (in Chinese)
20	HM Li. Basic and clinical research of “tonifying the kidney to regulate stem cells transforming the liver” for liver diseases. World Sci Technol/Modernization Tradit Chin Med Mater Med (Shi Jie Ke Xue Ji Shu—Zhong Yi Yao Xian Dai Hua) 2013; 15: 1425–1428 (in Chinese)
21	X Gao, ZH Ye, L Dai, HM Li. Molecular mechanism research of Zuogui Pill about “tonifying kidney to promote liver regeneration and repair by effecting stem cells and their microenvironment” by using the network pharmacology method. Chin J Integr Tradit West Med Liver Dis (Zhong Xi Yi Jie He Gan Bing Za Zhi) 2018; 28: 96–99 (in Chinese)
22	HM Li, X Gao, XS Yan, AP Ming, YQ Peng, JJ Li. Promotion effect of Zuoguiwan on bone marrow cells’ forming into liver cells in mice. World Chin J Dig (Shi Jie Hua Ren Xiao Hua Za Zhi) 2005; 13: 2818–2822 (in Chinese)
23	HM Li, G Xiang, XS Yan. Studies of Zuogui Wan medicated serum pharmacology based on the co-culture system of bone marrow stem cells and hepatocytes. J Clin Rehabil Tissue Eng Res (Zhongguo Zu Zhi Gong Cheng Yan Jiu Yu Lin Chuang Kang Fu) 2010; 14: 3527–3532 (in Chinese)
24	HM Li, XS Yan, JJ Luo, JJ Li, X Gao, AP Ming, YQ Peng. Effect of Zuogui Wan drug serum on the differentiation of bone marrow mesenchymal stem cells into hepatocytes. J Clin Rehabil Tissue Eng Res (Zhongguo Zu Zhi Gong Cheng Yan Jiu Yu Lin Chuang Kang Fu) 2007; 11: 5465–5468 (in Chinese)
25	HM Li, XS Yan, AP Ming, YQ Peng, JJ Luo, SB Lan, X Gao. The differentiation of marrow stromal cells into hepatocyte by conditioned medium of liver cells in vitro. Chin J Integr Tradit West Med Liver Dis (Zhong Xi Yi Jie He Gan Bing Za Zhi) 2005; 15: 28–30, 67 (in Chinese)
26	HM Li, WJ Gui, JJ Li, X Gao, XS Yan, Y Cheng. Effects of Zuoguiwan on the liver regeneration related gene signaling pathway in female mice with male mice bone marrow transplant. J Clin Rehabil Tissue Eng Res (Zhongguo Zu Zhi Gong Cheng Yan Jiu Yu Lin Chuang Kang Fu) 2008; 12: 6069–6073 (in Chinese)
27	HM Li, X Gao, XS Yan, AP Ming, YQ Peng. Analysis of gene expression profile of bone marrow cells forming liver cells. Chin J Integr Tradit West Med Liver Dis (Zhong Xi Yi Jie He Gan Bing Za Zhi) 2006; 16: 212–214, 217 (in Chinese)
28	HM Li, X Gao, MS Zhou. Effects of Zuogui Pill on gene expression profile of regenerate hepatic tissue in MSG-liver regeneration-rat. China J Tradit Chin Med Pharm (Zhonghua Zhong Yi Yao Za Zhi) 2006; 21: 104–106 (in Chinese)
29	HM Li, X Gao, MS Zhou. Zuogui Pill regulating gene expression profile in liver of MSG-induced liver regeneration in rats. Chin J Basic Med Tradit Chin Med (Zhongguo Zhong Yi Ji Chu Yi Xue Za Zhi) 2005; 11: 595–598 (in Chinese)
30	HM Li, ML Yang, JJ Mei, LT Zhang, XF Qiu. The effects of Zuogui Pill on expression of TGF-α,β and it’s receptor in ARN and regenerative liver of the MSG-regeneration-rat. Chin J Hepatol (Zhonghua Gan Zang Bing Za Zhi) 2004; 12(5): 307–308 (in Chinese) pmid: 15161515
31	HM Li, X Gao, ML Yang, JJ Mei, LT Zhang, XF Qiu. Effects of Zuogui Wan on neurocyte apoptosis and down-regulation of TGF-β1 expression in nuclei of arcuate hypothalamus of monosodium glutamate-liver regeneration rats. World J Gastroenterol 2004; 10(19): 2823–2826 https://doi.org/10.3748/wjg.v10.i19.2823 pmid: 15334678
32	HM Li, ML Yang, JJ Mei, LT Zhang, XF Qiu. Apoptosis of hypothalamic neural cell and genetic expression of TGF-β1 in MSG-liver regeneration-rats. Chin J Appl Physiol (Zhongguo Ying Yong Sheng Li Xue Za Zhi) 2003; 19: 46–47, 93 (in Chinese)
33	CL Xu, YH Hao, YP Lu, ZS Tang, XC Yang, J Wu, X Zheng, BJ Wang, J Liu, DL Yang. Upregulation of Toll-like receptor 4 on T cells in PBMCs is associated with disease aggravation of HBV-related acute-on-chronic liver failure. J Huazhong Univ Sci Technolog Med Sci 2015; 35(6): 910–915 https://doi.org/10.1007/s11596-015-1527-x pmid: 26670445
34	ZH Zhao, YC Fan, Q Zhao, CY Dou, XF Ji, J Zhao, S Gao, XY Li, K Wang. Promoter methylation status and expression of PPAR-g gene are associated with prognosis of acute-on-chronic hepatitis B liver failure. Clin Epigenetics 2015; 7(1): 115 https://doi.org/10.1186/s13148-015-0149-2 pmid: 26516376
35	K Fujiwara, S Yasui, O Yokosuka. Corticosteroid and nucleoside analogue for hepatitis B virus-related acute liver failure. World J Gastroenterol 2015; 21(36): 10485–10486 https://doi.org/10.3748/wjg.v21.i36.10485 pmid: 26420977
36	Z Cao, F Li, X Xiang, K Liu, Y Liu, W Tang, L Lin, Q Guo, S Bao, Q Xie, H Wang. Circulating cell death biomarker: good candidates of prognostic indicator for patients with hepatitis B virus related acute-on-chronic liver failure. Sci Rep 2015; 5(1): 14240 https://doi.org/10.1038/srep14240 pmid: 26383863
37	J Wang, Y Yu, Y Yang, SS Wu, HH Zhu, YN Liu, WX Liu, Y Hu, W Wu, CX Xia, Z Chen. Expression of serum sCD163 in patients with liver diseases and inflammatory disorders. Int J Clin Exp Pathol 2015; 8(7): 8419–8425 pmid: 26339412
38	D Porowski, A Wirkowska, E Hryniewiecka, J Wyzgał, M Pacholczyk, L Pączek. Liver failure impairs the intrahepatic elimination of interleukin-6, tumor necrosis factor-α, hepatocyte growth factor, and transforming growth factor-β. BioMed Res Int 2015; 2015: 934065 https://doi.org/10.1155/2015/934065 pmid: 26090463
39	W Zeng, J Xiao, G Zheng, F Xing, GL Tipoe, X Wang, C He, ZY Chen, Y Liu. Antioxidant treatment enhances human mesenchymal stem cell anti-stress ability and therapeutic efficacy in an acute liver failure model. Sci Rep 2015; 5(1): 11100 https://doi.org/10.1038/srep11100 pmid: 26057841
40	BM Manzini, A da Silva Santos Duarte, S Sankaramanivel, AL Ramos, P Latuf-Filho, C Escanhoela, P Kharmandayan, ST Olalla Saad, I Boin, AC Malheiros Luzo. Useful properties of undifferentiated mesenchymal stromal cells and adipose tissue as the source in liver-regenerative therapy studied in an animal model of severe acute fulminant hepatitis. Cytotherapy 2015; 17(8): 1052–1065 https://doi.org/10.1016/j.jcyt.2015.04.010 pmid: 26139545
41	HC Ma, XL Shi, HZ Ren, XW Yuan, YT Ding. Targeted migration of mesenchymal stem cells modified with CXCR4 to acute failing liver improves liver regeneration. World J Gastroenterol 2014; 20(40): 14884–14894 https://doi.org/10.3748/wjg.v20.i40.14884 pmid: 25356048
42	CH Chiang, WW Wu, HY Li, Y Chien, CC Sun, CH Peng, AT Lin, CS Huang, YH Lai, SH Chiou, SI Hung, YL Chang, YT Lan, DM Liu, CS Chien, TI Huo, SD Lee, CY Wang. Enhanced antioxidant capacity of dental pulp-derived iPSC-differentiated hepatocytes and liver regeneration by injectable HGF-releasing hydrogel in fulminant hepatic failure. Cell Transplant 2015; 24(3): 541–559 https://doi.org/10.3727/096368915X686986 pmid: 25668102
43	JA Cienfuegos, F Rotellar, J Baixauli, F Martínez-Regueira, F Pardo, JL Hernández-Lizoáin. Liver regeneration—the best kept secret. A model of tissue injury response. Rev Esp Enferm Dig 2014; 106(3): 171–194 pmid: 25007016
44	JQ Xiao, XL Shi, JJ Tan, L Zhang, Q Xu, YT Ding. A novel treatment regimen for acute liver failure based on a combination of mesenchymal stem cells transplantation and IL-lRa-loaded chitosan nanoparticles. Chin J Hepatol (Zhonghua Gan Zang Bing Za Zhi) 2013; 21(4): 308–314 (in Chinese) pmid: 24021796
45	JQ Xiao, XL Shi, HC Ma, JJ Tan, L zhang, Q Xu, YT Ding. Administration of IL-1Ra chitosan nanoparticles enhances the therapeutic efficacy of mesenchymal stem cell transplantation in acute liver failure. Arch Med Res 2013; 44(5): 370–379 https://doi.org/10.1016/j.arcmed.2013.06.004 pmid: 23916885
46	M Yoon, MY Kim. The anti-angiogenic herbal composition Ob-X from Morus alba, Melissa officinalis, and Artemisia capillaris regulates obesity in genetically obese ob/ob mice. Pharm Biol 2011; 49(6): 614–619 https://doi.org/10.3109/13880209.2010.539617 pmid: 21554004
47	T Zhang, D Chen. Anticomplementary principles of a Chinese multiherb remedy for the treatment and prevention of SARS. J Ethnopharmacol 2008; 117(2): 351–361 https://doi.org/10.1016/j.jep.2008.02.012 pmid: 18400428
48	JL Ríos. Chemical constituents and pharmacological properties of Poria cocos. Planta Med 2011; 77(7): 681–691 https://doi.org/10.1055/s-0030-1270823 pmid: 21347995
49	HY Lee, SW Kim, GH Lee, MK Choi, HW Chung, YC Lee, HR Kim, HJ Kwon, HJ Chae. Curcumin and Curcuma longa L. extract ameliorate lipid accumulation through the regulation of the endoplasmic reticulum redox and ER stress. Sci Rep 2017; 7(1): 6513 https://doi.org/10.1038/s41598-017-06872-y pmid: 28747775
50	R Uchio, Y Higashi, Y Kohama, K Kawasaki, T Hirao, K Muroyama, S Murosaki. A hot water extract of turmeric (Curcuma longa) suppresses acute ethanol-induced liver injury in mice by inhibiting hepatic oxidative stress and inflammatory cytokine production. J Nutr Sci 2017; 6: e3 https://doi.org/10.1017/jns.2016.43 pmid: 28620478
51	B Liang, XL Guo, J Jin, YC Ma, ZQ Feng. Glycyrrhizic acid inhibits apoptosis and fibrosis in carbon-tetrachloride-induced rat liver injury. World J Gastroenterol 2015; 21(17): 5271–5280 https://doi.org/10.3748/wjg.v21.i17.5271 pmid: 25954100
52	JH Isaza, H Ito, T Yoshida. A flavonol glycoside-lignan ester and accompanying acylated glucosides from Monochaetum multiflorum. Phytochemistry 2001; 58(2): 321–327 https://doi.org/10.1016/S0031-9422(01)00247-3 pmid: 11551558
53	CM Wang, RS Yuan, WY Zhuang, JH Sun, JY Wu, H Li, JG Chen. Schisandra polysaccharide inhibits hepatic lipid accumulation by downregulating expression of SREBPs in NAFLD mice. Lipids Health Dis 2016; 15(1): 195 https://doi.org/10.1186/s12944-016-0358-5 pmid: 27852305
54	WY Liao, TH Tsai, TY Ho, YW Lin, CY Cheng, CL Hsieh. Neuroprotective effect of paeonol mediates anti-inflammation via suppressing Toll-like receptor 2 and Toll-like receptor 4 signaling pathways in cerebral ischemia-reperfusion injured rats. Evid Based Complement Alternat Med 2016; 2016: 3704647 https://doi.org/10.1155/2016/3704647 pmid: 28101118
55	PJ Liu, MS Miao, JL Gao. Effect of gross polysaccharide of Radix Rehmanniae Preparata on levels of whole blood cells and serum macrophage colony stimulating factor in mice with both qi and blood deficiency. J Clin Rehabil Tissue Eng Res 2008; 12: 7543–7546
56	FS Li, HG Xu, MY Li, H Liu. Stndy on immunological properties of polysaccharide extracted from rehmanniae preparata. Chin J Publ Health 2008; 24: 1109–1110
57	RE Sherman, SA Anderson, GJ Dal Pan, GW Gray, T Gross, NL Hunter, L LaVange, D Marinac-Dabic, PW Marks, MA Robb, J Shuren, R Temple, J Woodcock, LQ Yue, RM Califf. Real-world evidence—what is it and what can it tell us? N Engl J Med 2016; 375(23): 2293–2297 https://doi.org/10.1056/NEJMsb1609216 pmid: 27959688

Viewed

Full text

Abstract

Cited

Shared

Discussed